FDA Approves Nasacort HFA for Allergic Rhinitis
Nasacort HFA (triamcinolone acetonide) is a dry-aerosol intranasal corticosteroid formulation containing hydrofluoroalkane (HFA). It replaces Nasacort Nasal Inhaler, which along with other nasal inhalers containing
CFC’s, was taken off the market to comply with Environmental
Protection Agency (EPA) and FDA requirements intended to protect
the ozone layer. Nasacort HFA Nasal Aerosol is indicated for the
treatment of nasal symptoms associated with seasonal and perennial
allergic rhinitis in adults and children age 6 and older.
Posted: April 2004